Arcutis Eyes Atopic Dermatitis Opportunity With Ducentis Buy
Paying Just $16m Upfront In Cash For UK Biotech
Arcutis's CEO believes that with "a modest investment," the company can generate proof-of-concept data "against a de-risked target in a high-value indication,” Ducentis's preclinical atopic dermatits drug DS-234.
